# OnCo record nct07683221 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07683221/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07683221", "NCT07683221" ;
  schema:name "SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic Cancer"@en ;
  schema:description "A phase 2 trial of sintilimab and gemcitabine + nab-paclitaxel in pancreatic cancer, run by Shandong Cancer Hospital and Institute, not yet recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07683221/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07683221> ;
  onco:status "planned" ;
  onco:tag "ctgov-ingest", "pancreatic-deep-dive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/locally-advanced-pdac/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/sbrt/> ;
  onco:drugs <https://onco.cc/drugs/sintilimab/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> .